Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more

Recent & Breaking News (NDAQ:VYNE)

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

GlobeNewswire 2 days ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

GlobeNewswire 7 days ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire March 19, 2024

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

GlobeNewswire February 29, 2024

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

GlobeNewswire February 27, 2024

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 21, 2024

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

GlobeNewswire January 10, 2024

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

GlobeNewswire January 3, 2024

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 13, 2023

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

GlobeNewswire November 7, 2023

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

GlobeNewswire November 1, 2023

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

GlobeNewswire October 30, 2023

VYNE Therapeutics Announces Private Placement of $88 Million

GlobeNewswire October 30, 2023

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

GlobeNewswire October 30, 2023

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 14, 2023

VYNE Therapeutics to Attend BIO International Convention

GlobeNewswire May 18, 2023

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

GlobeNewswire May 1, 2023

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

GlobeNewswire April 19, 2023